A diencephalic circuit for opioid analgesia but not positive reinforcement

Maggie W. Waung[1], Kayla A. Maanum[1], Joseph R. Driscoll[1], Chris O'Brien[2], Svetlana Bryant[2], Kasra Mansourian[1], Marisela Morales[3], David J. Barker[2,3], and Elyssa B. Margolis[1*†]

[1]UCSF Weill Institute for Neuroscience, Department of Neurology, University of California, San Francisco, CA, United States

[2]Department of Psychology, Rutgers University, New Brunswick, NJ, United States

[3]National Institute on Drug Abuse, Neuronal Networks Section, National Institutes of Health, Baltimore, MD, United States

*Corresponding Author

†Email: Elyssa.Margolis@ucsf.edu

Abstract

Mu opioid receptor (MOR) agonists are the most effective analgesics, but their use risks respiratory depression and addiction. The epithalamic lateral habenula (LHb) is a critical site that signals aversive states, often via indirect inhibition of reward circuitry, and MORs are highly expressed in the LHb. We found that the LHb is a potent site for MOR-agonist analgesia. Strikingly, LHb MOR activation generates negative reinforcement but is not rewarding in the absence of noxious input. While the LHb receives inputs from multiple sites, we found that inputs from the lateral preoptic area of the hypothalamus (LPO) are excited by noxious stimulation, express MOR mRNA, and are preferentially targeted by MOR selective agonists. Critically, optogenetic stimulation of LHb-projecting LPO neurons produces an aversive state relieved by LHb MOR activation. Therefore targeting this MOR sensitive forebrain circuit can relieve pain yet lower the risk of misuse by pain free individuals.

Introduction

Opioids are the most effective pain medications, but the risk of overdose and opioid use disorder limits their clinical utility. Uncoupling the analgesic actions of opioids from those that underlie positive reinforcement is a longstanding goal for pharmacotherapeutic development. Identifying circuits that can drive relief of ongoing pain but not reward in the absence of pain is a critical step towards this goal. The lateral habenula (LHb) may participate in such a circuit, which is not only activated in a pain setting[1–5] but also by other aversive states including reward omission[6], and animal models of depression[7]. Several CNS sites involved in pain signaling with reported strong inputs to the LHb include the lateral hypothalamus (LH)[8,9] and anterior cingulate cortex (ACC)[10–12]. Furthermore, efferents from the LHb target pain-responsive regions including the lateral periaqueductal gray, dorsal raphe, and parabrachial nucleus[13,14]. While morphine injections that covered a combination of the LHb, medial habenula, and posteromedial

24 thalamus reduce pain-related behavior in an acute pain model[15], whether these effects are due to MOR
25 activation specifically in the LHb is an open question.

26 Since increased activity in LHb neurons encodes aversive states including ongoing pain, inhibition of this
27 activity should relieve pain and generate negative reinforcement. We previously found that MOR
28 activation can decrease neural activity in the LHb via both postsynaptic hyperpolarization and inhibition
29 of glutamate release onto subsets of LHb neurons in naïve animals[16]. Here we investigated the specific
30 LHb input circuit and synaptic mechanism by which MOR activation in the LHb produces pain relief.
31 Among six potential inputs to the LHb, we determined that the glutamatergic innervation from the lateral
32 preoptic area of the hypothalamus (LPO) is both pain-responsive and most strongly inhibited by MOR
33 activation. Importantly, we show that activating MORs in this circuit in the absence of pain does not
34 produce reinforcement, suggesting that targeting this circuit could be a significant advance in pain
35 therapeutics.

36

37 **Results**

38 ***MOR activation in the LHb produces pain relief but not positive reinforcement***

39 To examine the behavioral impact of selective MOR activation in the LHb on ongoing pain, we used the
40 spared nerve injury (SNI) model of persistent neuropathic pain and implanted bilateral cannulae above the
41 LHb in Sprague Dawley rats (Fig. 1a). After recovery from surgery, we evaluated allodynia by measuring
42 mechanical stimulation thresholds with graded von Frey filaments. Bilateral microinjections of the MOR-
43 selective agonist DAMGO (10 μM; 300 nL/hemisphere) into the LHb increased the average hindpaw
44 withdrawal threshold compared to saline microinjections in the same animals, indicating that DAMGO
45 reduced the mechanical allodynia generated by SNI in male rats (Fig. 1b). In contrast, intra-LHb
46 DAMGO microinjections in sham-injured male rats had no effect on mechanical withdrawal thresholds
47 compared to saline (Fig. 1b). Consistent with the rat literature[17], we did not observe a significant decrease

Figure 1



Figure 1. *MOR activation in the LHb relieves allodynia and generates negative reinforcement in rats with neuropathic pain.* **a,** Timeline of behavioral experiments. Lower inset, example injection site centered in LHb. Scale bar = 500 μm. **b,** (Left) Violin plots of 50% mechanical withdrawal thresholds following saline or 10 μM DAMGO microinjections into the LHb in sham males (n = 9), SNI males (n = 8), and SNI females (n = 9). Sham males: Wilcoxon signed rank test, V = 1.5, p =1. SNI males: Wilcoxon signed rank test, V = 2, p = 0.050. Females trended towards an increase in threshold following DAMGO infusion: Wilcoxon signed rank test, V = 7, p = 0.074. (Right) Mechanical withdrawal thresholds in male rats with i.c.v. cannulae, with SNI (n = 12) or sham (n = 9) injuries. Sham: Wilcoxon signed rank test, V = 7, p = 0.53. SNI: Wilcoxon signed rank test, V = 31, p = 0.080. **c**, Difference scores before and after conditioning with intracranial microinjections. (Left) Males with SNI developed a preference for the chamber paired with intra-LHb DAMGO. Two-way mixed ANOVA, significant interaction between SNI/sham and baseline/test F(1,13) = 15.93, p = 0.002; post hoc effect group on test day adjusted p = 0.01; paired t-tests, sham adjusted p = 1; SNI adjusted p = 0.016. Female SNI animals trended towards a preference for the DAMGO-paired chamber: Paired t-test p = 0.054. (Right) i.c.v. DAMGO did not produce a preference in sham or SNI male rats: Two-way mixed ANOVA, F(1,19) = 2.239, p = 0.15. **d,** Mechanical withdrawal thresholds in sham (n = 6) and SNI (n = 9) female rats following 100 μM DAMGO infusions into the LHb. Sham: Wilcoxon signed rank test, V = 5, p = 1. SNI: Wilcoxon signed rank test, V = 6, p = 0.40. **e,** Place conditioning of sham and SNI females to intra-LHb 100 μM DAMGO vs saline. Females with SNI developed a significant CPP: Two-way mixed ANOVA, significant interaction between SNI/sham and baseline/test F(1,13) = 6.234, p = 0.027; post hoc effect group on test day adjusted p = 0.07; paired t-tests, sham adjusted p = 0.48; SNI adjusted p = 0.035. Means represented by horizontal lines; SEM and quartiles indicated by vertical lines with and without caps, respectively. *p ≤ 0.05, **p < 0.01

48 in withdrawal latency to heat in the Hargreaves test after SNI compared to sham-injured controls, and
49 DAMGO microinjections into the LHb did not alter heat withdrawal latency compared to saline in SNI or
50 in sham animals (Extended Data Fig. 1a). Intra-LHb DAMGO also reversed mechanical allodynia
51 induced by inflammatory pain in the CFA model (Extended Data Fig. 1b-g).

52 To evaluate whether MOR activation in the LHb influences the affective experience of pain, we used the
53 place conditioning paradigm in the same group of rats. In a three-chamber apparatus, we paired intra-LHb
54 DAMGO microinjections with one chamber and saline microinjections with the opposite side chamber.
55 Rats with SNI developed a significant conditioned place preference (CPP) for the LHb-DAMGO-paired
56 chamber, while sham-injured rats did not prefer either chamber following conditioning (Fig. 1c).

57 To rule out the potential confound of off-target effects due to DAMGO entering the CSF space via the
58 nearby third ventricle, we microinjected the same solutions intracerebroventricularly (i.c.v.) in male rats
59 with SNI or sham injury. This manipulation did not influence mechanical withdrawal thresholds
60 compared to saline microinjection in either group (Fig. 1b). Furthermore, i.c.v. DAMGO microinjections
61 did not generate a CPP in either SNI or sham animals (Fig. 1c). Therefore, we conclude that the
62 behavioral effects of our DAMGO microinjections were due to actions specifically in the LHb.

63 We also investigated whether LHb MOR activation had the same effects on allodynia and affective pain
64 in female rats. Using the same microinjection parameters as in male rats, female rats with SNI showed a
65 trend towards reduced mechanical allodynia following DAMGO microinjections into the LHb compared
66 to saline (Fig. 1b). Female rats with SNI also showed a trend towards a preference for the DAMGO-
67 paired chamber (Fig. 1c). As in males, females with SNI displayed no difference in heat withdrawal
68 latency between DAMGO and saline microinjections (Extended Data Fig. 1a). Because female rats may
69 be less sensitive to the analgesic effect of opioids[18,19], we tested a 10-fold higher concentration of intra-
70 LHb DAMGO (100 μM) in a separate cohort of females. This dose was chosen based on studies
71 demonstrating a three-fold reduction in i.c.v. DAMGO efficacy for females in the tail flick test[20]. The

72 higher DAMGO dose induced a significant CPP, though still did not reverse the mechanical allodynia in
73 female rats (Fig. 1d, e). Thus, we conclude that LHb MOR activation can reverse the affective experience
74 of pain without raising the baseline threshold for reflex withdrawal in both male and female rats.

75 ***MOR synaptic function persists in LHb neurons in animals with chronic pain***

76 In various CNS regions, chronic pain induces changes in MOR expression and function, including
77 downregulation[21–23]. We previously reported that in naïve male rats MOR activation inhibits glutamate
78 release onto a subset of LHb neurons and also hyperpolarizes approximately 30% of LHb neurons[16]. Here
79 we exampled whether these MOR effects are altered in a persistent pain state. To evaluate postsynaptic
80 MOR function we performed whole cell voltage clamp recordings of LHb neurons from acute brain slices
81 from male rats with SNI and measured DAMGO induced changes to holding current (Fig. 2a, b). These
82 responses did not differ from our observations in naïve rats. We also tested MOR inhibition of
83 glutamatergic electrically-evoked excitatory postsynaptic currents (EPSCs) in LHb neurons from animals
84 with SNI. These responses were also consistent with observations from naïve rats (Fig. 2c, d). We
85 conclude that these actions of MOR on LHb cell bodies and glutamatergic terminals do not change in
86 animals with ongoing pain.

87 Increased activity in LHb neurons as well as increased glutamatergic synaptic strength onto LHb neurons
88 are associated with aversive behavioral states[7,24,25]. To evaluate this in LHb neurons from animals with
89 SNI, we first measured the paired pulse ratio in the evoked EPSCs, a measure of probability of release.
90 There was no difference in paired pulse ratio between groups (Fig. 2e). We next compared the frequency
91 and magnitude of spontaneous glutamatergic EPSCs (sEPSCs) in animals with SNI to those in naïve
92 animals. Mean sEPSC frequency and amplitude were also similar in LHb neurons from SNI and naïve
93 animals (Fig. 2f, g). Together, these observations suggest a lack of synaptic plasticity induced on
94 glutamatergic inputs to LHb neurons by painful injury.

Figure 2



Figure 2. *Ongoing pain does not alter MOR agonist synaptic effects or probability of glutamate release in the LHb.* Responses to the MOR agonist DAMGO were recorded in voltage clamp, V_m = -60 mV. **a**, In animals with SNI, a subset of neurons responded to bath application of the MOR agonist DAMGO (500 nM) with a time locked outward current that was reversed with the MOR selective antagonist CTAP (500 nM). **b**, Postsynaptic holding current changes in response to bath application of DAMGO were not different between neurons from naïve and SNI rats: Unpaired t-test df = 32, t = 0.892, p = 0.379. **c**, In rats with SNI, DAMGO (500 nM) induced a time locked inhibition of electrically evoked glutamatergic EPSCs, and CTAP (500 nM) reversed the effect. **d**, This DAMGO inhibition of electrically evoked EPSC amplitude was not different between LHb neurons from naïve and SNI rats: Unpaired t-test df = 21, t = 0.137, p = 0.89. Baseline probability of release at glutamatergic synapses was similar between LHb neurons in naïve and SNI rats as measured by (**e**) paired pulse ratio (P2/P1) of electrically stimulated EPSCs (50 ms inter stimulus interval): Unpaired t-test, df = 24, t = 0.102, p = 0.92; (**f**) baseline spontaneous EPSC frequency: Unpaired t-test unequal variances, df = 37, t = -0.17, p = 0.87; and (**g**) spontaneous EPSC amplitude: Unpaired t-test unequal variances, df = 38, t = -0.09, p = 0.93. Data from naïve rats previously published in[16].

95 ***The LHb receives functional synaptic input from the LPO, LH, VTA, VP, and EPN, but not the ACC.***

96 LHb neuron firing activity increases with acute noxious stimulation, and an increase in ongoing firing
97 frequency is during aversive behavioral states[2,3,7]. In ongoing pain, since we did not observe evidence for
98 changes in glutamatergic synaptic strength, such increases in firing may be driven by greater activity in
99 the glutamatergic axons innervating LHb neurons. Therefore, we hypothesized that the intra-LHb
100 DAMGO-induced behavioral effects that we observed in injured animals were due to MOR inhibition of
101 glutamatergic axon terminals, thus decreasing the aversive excitatory drive onto the LHb neurons. Since
102 MOR activation only inhibits glutamatergic inputs onto a subset of LHb neurons[16], MORs might be
103 preferentially expressed on specific afferent inputs. Prior work characterizing direct functional synaptic
104 connections to the LHb is limited to mice[26], therefore first we sought to confirm these functional
105 connections in the rat. We investigated inputs from the entopeduncular nucleus (EPN), lateral preoptic
106 area of the hypothalamus (LPO), and ventral tegmental area (VTA) because stimulating glutamatergic
107 LHb inputs from these sources has been shown to be aversive[24,27,28]. We also investigated inputs from the
108 LH and ACC that are strongly implicated in pain processing[29] and the VP because stimulating
109 glutamatergic VP neurons increases the firing rate of LHb neurons[30]. We injected AAV2-hSyn-
110 hChR2(H134R)-mCherry into one of these six regions in order to express channelrhodopsin (ChR2) in
111 these different input populations (Fig. 3a). We then made whole cell recordings in LHb neurons and
112 measured light-evoked synaptic inputs while blind to injection site. ChR2 was activated by an LED (λ =
113 473) coupled to an optic fiber placed approximately 100 µm from the recorded cell. Post synaptic currents
114 (PSCs) were measured in response to paired light pulses (1 or 5 ms, 50 ms inter stimulus interval) at
115 holding potentials of -60 mV and -40 mV to probe for EPSCs and $GABA_AR$ mediated inhibitory PSCs
116 (IPSCs) in each cell, respectively. Roughly similar proportions of LHb neurons received synaptic input
117 from each of these targets, with the exception of the ACC, where we did not detect any fast PSC
118 connections (Fig. 3b, topographical distribution of connected neurons in Extended Data Fig. 2). The
119 absence of a functional synaptic input from the ACC to the LHb was surprising, as both anterograde[10,12]

Figure 3



Figure 3. *Glutamatergic inputs to the LHb from the LPO are inhibited by MOR activation.* **a,** Schematic diagram of AAV2-hSyn-hChR2(H134R)-mCherry injection targets which project to the LHb. **b**, Proportions of LHb neurons receiving functional synaptic connections from six input regions measured with optogenetic stimulation of terminals expressing ChR2. **c**, Among connected neurons, venn diagrams depict the numbers of LHb cells receiving optically stimulated glutamatergic and/or GABAergic synaptic input. **d,** (Left) Experiment design: DAMGO (500 nM) was applied during optical synaptic stimulation experiments to probe for functional MOR presynaptic control of glutamate release from specific inputs. (Right) Change from baseline amplitude of optically-evoked EPSCs during DAMGO application. EPSCs from LPO terminal stimulation were most strongly inhibited by MOR activation: One-way ANOVA, df = 4, F = 4.11, p = 0.0057 followed by Tukey HSD pairwise comparisons. **e**, (Left) Representative traces of optically-evoked EPSCs in an LHb neuron from a rat with ChR2 expressed in inputs from the LPO. DAMGO decreased the amplitude of light-evoked EPSC, which was partially reversed by the selective MOR antagonist CTAP (500 nM). Rise time was < 2 ms, indicative of a monosynaptic response. (Right) Summary time course of the DAMGO inhibition across all optically-evoked LPO-LHb EPSCs (n = 12). f, LPO inputs to the LHb in female rats (left) had a similar overall connectivity rate but (middle) more GABAergic connections than glutamate connections. (Right) DAMGO inhibited light-evoked glutamatergic synaptic inputs from the LPO to the LHb in female rats as well.

120 and retrograde tracers[11] have previously demonstrated modest inputs. Moreover, the ACC is extensively
121 implicated in behavioral responses to pain and MOR-agonist induced pain relief[31,32]. As a secondary
122 measure of the strength of the innervation, we performed a systematic evaluation of the potential
123 connection using ChR2 as an anterograde tracer, making large injections of AAV2-hSyn-hChR2(H134R)-
124 mCherry throughout the anteroposterior range of the ACC (Extended Data Fig. 3a). This tracing revealed
125 extensive innervation of the nearby mediodorsal thalamus (MDL), but minimal stereologically-quantified
126 labeling in the LHb (Extended Data Fig. 3b, c). Therefore, while we cannot completely rule out a
127 functional input from the ACC to the LHb, the innervation is extremely small compared to the other
128 sources of input to the LHb investigated here.

129 For each brain region from which fast synaptic PSCs were detected in the LHb, both glutamate and
130 GABA inputs were observed in varying proportions (Fig. 3c). Interestingly, while for each input there
131 were individual LHb neurons that received both glutamate and GABA synaptic connections, for each
132 input more than half of the connected LHb neurons received just one type of fast PSC, in varying
133 proportions. The VTA was the only input where more LHb neurons received GABAergic synaptic
134 connections than glutamatergic synaptic connections. Among observed synaptic connections, a wide
135 range of EPSC and IPSC amplitudes were observed for most of the inputs, except for the glutamatergic
136 inputs from the VTA that were consistently small (Extended Data Fig. 4a,c). The delay to light evoked
137 EPSC onset also varied across input source, with LH inputs having the shortest mean latency (Extended
138 Data Fig. 4b).

139 The nature of local LHb neural connections will also impact the circuit's response to MOR activation.
140 There are strong local glutamatergic connections within the LHb[16,33], but there is recent evidence both
141 for[34,35] and against[36,37] the existence of local GABA interneurons. As we only observed somatodendritic
142 MOR responses in a subset of LHb neurons, evidence for GABAergic interneurons in the LHb would
143 impact our model of how MOR activation modulates LHb neural activity, if such interneurons
144 preferentially express the MOR. In the rat, a small number of GAD1 positive neurons are present in the

145 lateral LHb, though these neurons do not co-express vesicular GABA transporter[36], the protein required
146 for loading GABA into synaptic vesicles. In order to detect functional local GABAergic connections
147 within the rat LHb, we injected AAV2-hSyn-hChR2(H134R)-mCherry into the LHb and recorded from
148 LHb neurons. Because some recorded neurons expressed ChR2, we measured light responses before and
149 after application of receptor antagonists in order to isolate the synaptically driven response from the ChR2
150 mediated currents. Under these conditions we did not observe any light activated local IPSCs in LHb
151 neurons (Extended Data Fig. 5). As expected, many neurons received local glutamatergic inputs
152 (Extended Data Fig. 5). We conclude that there is very limited or no local GABAergic interneuron
153 connectivity in the LHb of adult rats.

154 ***MOR activation most strongly inhibits LPO inputs to the LHb***

155 Next, we tested for functional MOR modulation of the light evoked glutamatergic inputs to LHb neurons
156 from each of the regions characterized above. DAMGO induced the strongest and most consistent
157 inhibitions in the terminals arising from LPO neurons (Fig. 3d, e). On average the inhibition was greater
158 in these LPO inputs than the MOR impact on ESPCs observed from the LH, VTA, VP, or EPN (Fig. 3d).
159 We also tested whether MOR inhibits LPO glutamatergic inputs to the LHb independent of sex; the mean
160 inhibition of glutamate release from LPO terminals to LHb neurons in female rats was equivalent to that
161 observed in males (Fig. 3f). Because of the prevalence of local glutamatergic connections in the LHb[16,33]
162 (Extended Data Fig. 5) and postsynaptic MOR inhibition of a subset of LHb neurons[16], we sought to rule
163 out a polysynaptic connection. First, a polysynaptic contribution seems unlikely for all of the
164 glutamatergic inputs reported here because the delay from light pulse onset to EPSC onset was
165 consistently less than 3 ms (Extended Data Fig. 4b). Second, to directly test isolated monosynaptic
166 connections, we expressed ChR2 in LPO neurons and recorded in the LHb; in neurons with light evoked
167 EPSC responses, we applied tetrodotoxin (TTX, 500 nM) and 4-aminopyridine (4 AP; 10 μM). In 8 of 8
168 tested neurons the light evoked EPSCs persisted in this monosynaptic signal sparing preparation, and this
169 monosynaptic response was inhibited by DAMGO in all 5 tested neurons (Extended Data Fig. 6).

170 Therefore, we conclude that MORs are functionally expressed on LPO terminals that monosynaptically
171 contact LHb neurons, and when these glutamatergic inputs are activated *in vivo*, DAMGO application
172 should inhibit them.

173 ***MOR mRNA is enriched in LHb-projecting LPO neurons***

174 Multiple basal forebrain structures express high levels of MOR including the VP, medial preoptic area
175 (MPO), horizontal diagonal band (HDB), ventral bed nucleus of the stria terminalis (vBNST), and other
176 regions of the extended amygdala complex (EAC)[38]. Some of these not only express MOR to a greater
177 extent than the LPO, but they also project to the LHb. To further evaluate the specificity of MOR
178 expression in LHb-projecting neurons in the LPO compared to nearby brain regions, we performed *in situ*
179 hybridization for MOR mRNA (OPRM1) in brain slices from Sprague Dawley rats where the retrograde
180 tracer Fluoro-Gold had been iontophoresed into the LHb (Fig. 4a - c). With this independent approach,
181 the LHb-projecting LPO neurons showed the strongest OPRM1 expression and contained the greatest
182 number of retrogradely labeled FG(+) neurons co-labeled for OPRM1 (112 ± 9 cells), corresponding to
183 57.1% ± 4.3% of all MOR(+)/FG(+) neurons in the basal forebrain (336/602 total cells). Inputs were also
184 observed from the HDB (23.6% ± 5.9% of MOR(+) cells; 153/602 total cells), VP (9.5% ± 3.1% of
185 MOR(+) cells; 52/602 total cells), MPO (3.0% ± 1.1% of MOR(+) cells; 19/602 total cells), vBNST
186 (3.7% ± 1.2% of MOR(+) cells; 23/602 total cells) and EAC (3.0% ± 2.1% MOR(+) cells; 19/602 total
187 cells; Fig. 4d - f). Overall, these anatomical data are highly consistent with our electrophysiology results,
188 supporting the conclusion that the LPO projection to the LHb is strongly regulated by MORs.

189 ***Noxious stimulation activates glutamatergic LHb-projecting LPO neurons***

190 We next tested whether glutamatergic LHb-projecting LPO neurons are activated by noxious stimulation
191 and whether ongoing pain alters this response. We expressed the calcium indicator GCaMP6m in LHb-
192 projecting LPO neurons using a Cre-dependent, retrograde viral construct HSV-hEF1α-LS1L-GCaMP6m
193 injected to the LHb of VGluT2::Cre mice (Fig. 5a). We implanted optic fibers above the LPO in control

Figure 4



Figure 4. *LPO inputs to the LHb highly express MOR mRNA.* **a,** Schematic of unilateral iontophoretic deposition of the retrograde tracer FG into the LHb. **b**, FG injection sites in LHb (n = 3 rats). **c,** (Left and middle) Representative brightfield images of FG-positive/MOR-positive somas (yellow arrowhead) and FG-positive/MOR-negative somas (blue arrowhead) in the LPO. Scale bar = 20 µm. (Right) Darkfield image of in situ hybridization localization for MOR mRNA (OPRM1). **d,** Number of MOR-positive/FG-positive (yellow) and MOR-negative/FG-positive (blue) cells in various basal forebrain regions. **e**, Donut plot depicting proportions of total MOR-positive inputs to the LHb from various basal forebrain regions. **f,** Locations of FG-positive/MOR-positive (red) and FG-positive/MOR-negative (blue) somata throughout basal forebrain. Co-labeled cells are separated from the singly labelled population for display purposes.

Figure 5



Figure 5. *LHb MOR activation relieves aversiveness of glutamatergic LPO input to the LHb*. **a,** (Top) Schematic diagram of HSV-hEF1α-LS1L-GCaMP6m injection into the LHb of VGluT2::Cre mice, to induce expression of GCaMP6m in glutamatergic LPO neurons innervating the LHb, and optic fiber implant for fiber photometry imaging in the LHb-projecting LPO neurons. (Bottom) Experimental timeline. **b**, Mice with SNI (n = 5) exhibited significantly larger changes in GCaMP6m fluorescence time-locked to paw withdrawal in response to thermal stimulation in the Hargreaves apparatus compared to sham controls (n = 9): Two-way ANOVA, $F(1,12) = 5.439$, $p = 0.038$; Holm-Sidak post-hoc test, $p = 0.0074$. **c**, (Left) Schematic diagram of dual virus injections to express ChR2-mCherry or mCherry selectively in LPO neurons that project to the LHb, optic fiber implantation targeting the LPO cell bodies, and cannula implantation targeting the LHb for experiments in male rats. (Right) Rats received bilateral blue light stimulation of the LPO during all conditioning sessions and in both chambers, sides paired with intra-LHb saline or DAMGO. **d**, Representative images of Cre-dependent ChR2-mCherry fluorescence in LPO cell bodies. (Left) Scale bar = 250 µm. (Right) Lesion from optic fiber ("o.f.") implant amidst ChR2-mCherry-expressing cell bodies. Scale bar = 50 µm. **e,** Only animals with active ChR2 (n = 8), but not mCherry controls (n = 8), developed a preference for the intra-LHb DAMGO paired side of the place conditioning apparatus. Two-way mixed ANOVA, significant interaction between ChR2-mCherry/mCherry and baseline/test $F(1,14) = 9.982$, $p = 0.007$; post hoc effect group on test day adjusted $p = 0.006$; paired t-tests, mCherry adjusted $p = 0.427$; ChR2-mCherry adjusted $p = 0.0027$. $^{**}p < 0.01$, $^{***}p < 0.005$

194 and SNI mice and performed fiber photometry prior to and during the Hargreaves task. On average,
195 GCaMP6m signal increased as paw withdrawal commenced, and this response was greatly potentiated in
196 mice with SNI (Fig. 5b), who also displayed shorter withdrawal latencies to heat (Extended Data Fig. 7).
197 Thus, glutamatergic LPO neurons that project to the LHb are activated in response to noxious peripheral
198 stimulation, and the magnitude of activation is higher during ongoing pain.

199 ***LHb MOR activation blocks the aversiveness of LPO-LHb stimulation***

200 Because LHb-projecting LPO glutamatergic neurons are activated by noxious stimulation, stimulating
201 these terminals in the LHb is aversive[28], and MOR activation inhibits these terminals in the LHb, we
202 hypothesized that the aversiveness produced by stimulating the LHb-projecting LPO neurons should be
203 reduced by MOR agonist injection into the LHb. To selectively express ChR2 in LHb-projecting LPO
204 neurons, we used an intersectional viral approach in rats, injecting the retrograde CAV-Cre into the LHb
205 and AAV2-EF1α-DIO-hChR2(H134R)-mCherry (or AAV2-EF1α-DIO-mCherry for controls) into the
206 LPO bilaterally (Fig. 5c,d). Bilateral optic fibers were subsequently implanted above the LPO and
207 cannulae were implanted above the LHb (Fig. 5c). During place conditioning sessions, rats received blue
208 light activation (473 nm, 20 Hz, 5 ms, 10-12 mW) of the LHb-projecting LPO neurons in both
209 environments of the place conditioning apparatus; chambers were paired with either intra-LHb DAMGO
210 or saline (Fig. 5c). Rats with ChR2 expression developed a CPP for the chamber associated with
211 DAMGO, while control mCherry expressing animals did not (Fig. 5e). Therefore, MOR activation in the
212 LHb blocked the aversiveness of stimulating the LPO input to the LHb without producing positive
213 reinforcement in the absence of input stimulation.

214

215 **Discussion**

216 Here we identified a circuit that can be targeted by MOR agonists to relieve the aversiveness of ongoing
217 pain but does not produce reward in pain free rodents. MOR agonist action in the LHb was sufficient to

218 reverse injury-induced allodynia and to produce a CPP, decreasing both sensory and affective pain
219 responses, respectively. Importantly, sham-injured animals did not develop a CPP, indicating that MOR
220 activation in the LHb does not produce positive reinforcement in the absence of pain. Unexpectedly,
221 rather than inputs from brain regions previously established as mediating pain and opioid-induced pain
222 relief, it is the glutamatergic inputs from the LPO that we demonstrate here are preferentially controlled
223 by LHb MOR activation. We found that the aversiveness produced by optogenetic activation of LHb-
224 projecting LPO neurons is blocked by MOR agonist microinjection into the LHb, showing that a MOR
225 inhibitory action on this circuit is sufficient to relieve pain. Together, these experiments show that MOR
226 activation in the LHb can generate negative reinforcement via pain relief, but not positive reinforcement
227 in the absence of noxious stimuli.

228 ***The LHb in pain and relief***

229 The LHb plays a role in the perception of noxious stimuli in injury and depression models[39,40], and most
230 LHb neurons fire more in aversive behavioral states and in response to noxious stimuli[2,3] Bilateral lesions
231 of the LHb decrease allodynia in the chronic constriction ischemia model of neuropathic pain in rats[41],
232 supporting the notion that signaling through the LHb contributes to injury-induced mechanical allodynia.
233 Chemogenetic inhibition of the LHb relieves thermal hyperalgesia in animals undergoing alcohol
234 withdrawal[39]. We found that MOR activation in the LHb reverses mechanical allodynia in a model of
235 neuropathic pain in both males and females. Together these observations support our conclusion that
236 MOR activation impacts the behavioral state of the animal by decreasing LHb neural activity *in vivo*. We
237 previously found two potential mechanisms by which MOR activation could inhibit LHb neural activity
238 in animals with ongoing pain: presynaptically inhibiting glutamate release and postsynaptically driving an
239 outward current in a subset of LHb neurons[16]. Here we found that intra-LHb MOR activation induces
240 negative reinforcement in both male and female rats with ongoing pain. Yet sham controls (male or
241 female) did not develop a CPP to intra-LHb DAMGO. Because the behavioral effect of MOR activation

242 was specific to injured rats we hypothesized that increased glutamatergic drive to the LHb, in an input
243 that is MOR sensitive, is a key element in the LHb circuit dynamics involved in pain and relief.

244 The vast majority of LHb neurons are glutamatergic, and there is anatomical evidence for dense bouton-
245 like structures arising from local LHb neurons[42]. This local feed forward connectivity may distribute a
246 specific excitatory LHb input across the various LHb projections that include the dorsal raphe,
247 ventrolateral PAG, MDL, centromedian thalamus, LH, RMTg, and VTA[9,13,14,43]. Local connectivity has
248 also been observed with functional assays, including that TTX application decreases the frequency of
249 sEPSC and sEPSP events in a subset of LHb neurons[16,33] and that optogenetic activation of LHb neurons
250 induces glutamatergic EPSCs (Extended Data Fig. 5). This feed forward circuit enables the distribution of
251 an afferent excitatory signal across LHb neurons, and it raises the possibility that inhibition of such an
252 input by a MOR agonist will decrease activity in LHb projection neurons, even those that are not directly
253 innervated by the excited pathway. Therefore, it is possible that MOR inhibition of one specific input,
254 such as the LPO, can decrease the excitatory drive onto many efferent LHb projections.

255 We characterized the functional glutamatergic connections from a variety of brain regions to the LHb in
256 rats; our findings were largely consistent with prior reports utilizing similar techniques in mice. Still, we
257 note that outcomes of these experiments are dependent on the types and number of neurons that express
258 ChR2 following the virus injections and are limited to the geometry of an injection site. We detected the
259 strongest glutamatergic inputs from the LH and EPN, while glutamatergic synaptic responses from the
260 VTA were quite small. We found no functional inputs from the ACC, and in a systematic anatomical
261 analysis we detected very few afferent fibers from the ACC in the LHb. Of the detected glutamatergic
262 inputs, we expected brain regions associated with pain perception and pain relief, such as the LH and
263 VTA, to be more strongly modulated by MOR activation. However, we instead found MOR mRNA and
264 function were clearly enriched in LPO inputs to the LHb.

265 ***The LPO: a brain region contributing to pain perception***

266 Because LHb neurons generally fire more in response to noxious stimuli, and optogenetic stimulation of
267 various glutamatergic inputs to the LHb is uniformly aversive[25,27,28,44,45], we hypothesized that a
268 glutamatergic input to the LHb transmits the pain signal. Further, aversive stressors lead to an increase in
269 the ratio of excitatory glutamatergic to inhibitory GABAergic in synaptic input to LHb neurons[44,45], and
270 restoration of this ratio is associated with relief of aversive states such as foot shock-induced learned
271 helplessness[45] and cocaine withdrawal[44]. Therefore, a pharmacological manipulation that decreases the
272 excitatory drive onto LHb neurons should also relieve aversive states. Because we found that DAMGO in
273 the LHb generates CPP only in animals with ongoing pain, our data suggest a MOR-sensitive
274 glutamatergic input to the LHb is active during pain and relatively inactive in the absence of pain.

275 The LPO projection to the LHb is composed of neurons releasing either glutamate or GABA; these
276 neurons do not co-release glutamate and GABA[28], unlike other LHb inpus[46]. Optogenetic activation of
277 LPO glutamate projections to the LHb is aversive[28], and here we posited that this activation mimics an
278 ongoing pain signal. We were able to relieve the aversiveness of activation of this connection with a
279 MOR agonist in the LHb. While a causal role for the LPO in pain perception is unexplored to date,
280 anterograde[47] and retrograde[48] tracing has shown a direct input to the LPO from the spinal cord. Also,
281 injections of the pro-inflammatory cytokine IL-1ß into the LPO induces hyperalgesia, indicating LPO
282 participation in a nociception circuit[49]. Painful stimuli such as subcutaneous formalin injections, mild
283 electric shock and tail pinch also increase firing in some LPO neurons[50,51]. Here we show that a major
284 output for LPO pain signals is to the LHb.

285 ***The LPO to LHb circuit: A unique target for analgesia***

286 Opioids remain the best available clinical analgesics, yet ongoing systemically administered opioids can
287 result in the serious adverse consequences including opioid use disorder and respiratory depression[52].
288 Opioid-induced positive reinforcement and euphoria, combined with the development of dependence,

289 underlie opioid abuse liability. To date, there is little clinical evidence that the analgesic and euphoric
290 effects of opioids can be decoupled in humans, yet this possibility is a potential pathway to improve
291 therapies for pain. Here we have identified a key circuit whose modulation relieves pain but does not
292 generate reward in the absence of pain. This dissociation between negative and positive reinforcement
293 provides a neural target to achieve pain relief without promoting substance use disorder. Is it possible to
294 activate MORs in the LHb but not in a reward circuit?

295 There is some preclinical evidence that this dissociation is possible by developing MOR ligands with the
296 appropriate opioid pharmacology. For example, a novel, cyclized, stabilized MOR selective agonist based
297 on endomorphin I produces pain relief but not reward[53]. An alternative approach would be to target a
298 different receptor with high expression levels in this circuit in a way that would decrease LHb neural
299 activity. Relevant to this approach, mRNA expression for a selection of orphan G-protein coupled
300 receptors (GPCRs) is enriched in the habenula[37,54,55]. One such receptor is GPR151, and LHb neurons
301 containing GPR151 receive input from the LPO[56]. Such directed strategies present a range of new
302 anatomic and molecular targets for pain therapy. By identifying the LPO-LHb connection as a site able to
303 provide relief from neuropathic pain and injury-induced allodynia, we have discovered a unique circuit
304 that may achieve effective opioid-mediated pain relief independent of the drug's addictive properties.

305

306 **Online Methods**

307 ***Animals***

308 All experiments were performed in accordance to the guidelines of the National Institutes of Health Guide
309 for the Care and Use of Laboratory Animals, and the Institutional Animal Care and Use Committees
310 (IACUC) at the University of California, San Francisco, the National Institute on Drug Abuse (NIDA),
311 and Rutgers University.

312 Male and female Sprague Dawley rats were obtained from Charles River Laboratories. Rats were allowed
313 access to food and water *ad libitum* and maintained on a 12h:12h light/dark cycle. Rats used in behavioral
314 and *in situ* hybridization studies were housed under reverse light/dark cycle conditions. Rats were group
315 housed until they underwent surgery, after which they were singly housed.

316 Male and female VGluT2::Cre mice were bred from mice obtained from the Jackson Laboratory (Jax #
317 016963). Mice were allowed access to food and water *ad libitum* and maintained on a 12h:12h light/dark
318 cycle with lights on at 7 AM. Mice were always housed in groups of 2-5.

319 ***Viral constructs***

320 AAV2-hSyn-hChR2(H134R)-mCherry (titer: 2.9e+12), AAV2-hSyn-mCherry (titer: 4.7e+12), and
321 AAV2-EF1α-DIO-ChR2-mCherry (titer: 5.1e+12) were purchased from the University of North Carolina
322 Vector Core with available stock constructs from the laboratory of K. Deisseroth at Stanford University.
323 CAV-Cre (titer: 2.5e+12) was purchased from Montpelier University, France. HSV-hEF1α-GCaMP6m
324 (titer: 5e+9) was purchased from the Gene Delivery Technology Core at Massachusetts General Hospital.

325 ***Stereotaxic injections***

326 Rats weighing 275-300 g were anesthetized with 3-5% isoflurane (Henry Schein) via inhalation and
327 secured in a stereotaxic frame. Bilateral craniotomies were created with a dental drill above the injection
328 site. For electrophysiology experiments, injections of AAV2-hSyn-hChR2(H134R)-mCherry were made
329 bilaterally into the LPO (-0.3 mm anteroposterior (AP), ±1.4 mm mediolateral (ML), -8.4 mm
330 dorsoventral (DV)), VP (-0.24 mm AP, ±2.6 mm ML, -7.8 mm DV), EPN (-2.4 mm AP, ±3.0 mm ML, -
331 7.0 mm DV), LH (-2.6 mm AP, ±1.7 mm ML, -8.2 mm DV), VTA (-5.8 mm AP, ±0.5 mm ML, -8.5 mm
332 DV), anterior ACC (+2.2 mm AP, ±0.6 mm ML, -2.6 mm DV), or posterior ACC (+1.7 AP, ±0.6 mm
333 ML, -2.6 mm DV) using a Nanoject II (Drummond Scientific, Broomall, PA). A volume of ~500-830 nL
334 was injected per hemisphere over a period of 4.5 min. The glass injector tip was left in place for at least 2

335 additional minutes before slow withdrawal to prevent backflow and infection of tissue dorsal to the
336 injection target.

337 For ChR2 behavior experiments, AAV2-EF1α-DIO-hChR2(H134R)-mCherry or AAV2-EF1α-DIO-
338 mCherry were injected into the LPO as above and CAV-Cre was injected bilaterally into the LHb (-3.7
339 mm AP, ±0.65 mm ML, -5.4 mm DV) with a microinjector connected via polypropylene tubing to
340 Hamilton syringes controlled by a dual syringe pump (KD pump) guided by a bilateral 33G stainless steel
341 guide cannula (Plastics One).

342 Rats were treated with subcutaneous Carprofen (5 mg/kg, Zoetis) and topical 2% Lidocaine (Phoenix
343 Pharmaceutical, Inc.) during the surgery for pain control. After surgery, animals had access to liquid
344 Tylenol (~1:40) in their drinking water for 3-5 days or were administered Meloxicam (s.c. 2mg/kg,
345 Pivetal) once per day for two days.

346 ***Cannulation and optic fiber implantation***

347 Two to four weeks after virus injection, rats slated for behavioral testing underwent a second cranial
348 surgery to implant custom-made 200 μm optic fibers at a 5° angle of rotation in the coronal plane into the
349 bilateral LPO (-0.6 mm AP, ± 3.05 mm ML, -7.5 mm DV). For microinjections into the LHb, bilateral
350 guide cannulae were implanted 1 mm above the LHb (-3.7 mm AP, ± 0.65 mm ML, -4.4 mm DV). A
351 dummy stylet was inserted to maintain patency of the cannulae. Optic fibers and cannulae were anchored
352 with flat point screws and dental cement. For i.c.v. microinjections, unilateral cannulae were implanted
353 into the right lateral ventricle (-1.0 mm AP, + 1.5 mm ML, -3.5 mm DV).

354 Analgesia during surgery and recovery was administered as described above. Animals were allowed to
355 recover for 1-2 weeks prior to behavioral testing. All virus injections, optic fiber and cannulae placements
356 were histologically verified postmortem based on the standard rat brain atlas[57].

357 ***Spared nerve injury***

358 Spared nerve injury (SNI) of the sciatic nerve branch was performed to model chronic neuropathic pain[17].
359 Under isoflurane anesthesia, a 2-cm skin incision was made over the left hindlimb. The biceps femoris
360 muscle was blunt dissected to expose the branches of the sciatic nerve. The common peroneal and tibial
361 nerves were ligated with 5.0 silk surgical suture and transected distally, with sparing of the sural nerve
362 branch. For sham procedures, a skin incision was made and biceps femoris muscle was exposed without
363 dissection. The overlying skin was closed with a monocryl suture. Animals were allowed seven days to
364 recover from surgery prior to behavioral testing. A majority of animals demonstrated decreased
365 mechanical withdrawal thresholds after SNI; those that did not demonstrate allodynia were not used in
366 further experiments.

367 ***Inflammatory pain model***

368 Peripheral inflammation was induced using Complete Freund's Adjuvant (CFA; Sigma Life Science).
369 Under isofluorane anesthesia, a 1:1 emulsion of CFA and sterile saline (150 μL) was injected into the
370 footpad of the rat's left hindpaw with a 27 G needle. Sham-injured controls were injected with sterile
371 saline (150 μL).

372 ***Microinjections***

373 Rats were lightly restrained in a cloth wrap for intracranial microinjections. A bilateral 33G microinjector
374 (PlasticsOne) that extended 1 mm ventrally beyond the guide cannula was inserted to target drug delivery
375 into the LHb or i.c.v. Hamilton syringes were driven by a dual syringe pump to infuse either vehicle
376 (phosphate buffered saline, PBS) or DAMGO (10 μM, 300 nL/hemisphere administered over 2 min). A
377 separate cohort of female rats was microinjected with 100 μM DAMGO.

378 ***von Frey sensory assessment***

379 Standard von Frey sensory assessments were performed as described[58]. Briefly, rats were habituated to
380 sensory testing chambers (Plexiglass boxes with mesh-like flooring) for at least 2 days prior to testing.
381 Behavioral assessments did not begin until exploratory behavior subsided. Testing was completed with
382 eight Touch Test ® fibers (North Coast Medical & Rehabilitation Products, Gilroy, CA, USA) ranging
383 from 0.4 to 15 g. Fibers were pressed perpendicularly to the mid-plantar left hindpaw with sufficient force
384 to cause bending in the fiber and held for 3-4 s. A positive response was noted if the paw was sharply
385 withdrawn. Ambulation was not considered a positive response. When responding was ambiguous, testing
386 was repeated. 50% withdrawal thresholds were calculated using fiber application in ascending stiffness
387 order or using the up down method.

388 In behavioral pharmacology experiments rats underwent sensory testing 5 min after counterbalanced
389 saline or DAMGO microinjections on the same day, with at least 4 h between infusions. Experimenters
390 were blinded to the solution composition during administration and testing.

391 ***Hargreaves sensory assessment***

392 Hargreaves tests were completed in sensory testing chambers with glass flooring. Assessment
393 commenced after rats acclimated to the chamber. Testing was completed using a plantar test analgesia
394 meter (Series 8 Model 390, IITC Life Science, Woodhills, CA, USA). Radiant light was directed toward
395 the mid-plantar left hindpaw until a sharp paw withdrawal response was observed with a 30 s maximum
396 cutoff. Ambulation was not considered a positive response. At baseline testing, measurements were
397 repeated at different intensity levels until the average withdrawal latency of eight trials was 15 ± 2 s.
398 Subsequent measurements were performed using this individualized intensity level.

399 ***Place conditioning***

400 Conditioned place preference (CPP) pairings occurred twice daily for four consecutive days following the
401 post-surgery sensory tests with DAMGO and saline. The conditioning apparatus (Med. Associates,

402 Georgia, VT, USA) was divided into two chambers (25 cm x 21 cm x 21 cm) with distinct visual
403 (horizontal vs. vertical stripes) and textural (thick vs. thin mesh flooring) cues, separated by a third,
404 smaller gray chamber (12 cm x 21 cm x 21 cm). Before conditioning commenced, animals were allowed
405 up to three opportunities to show neutrality across the chambers during 30-minute baseline sessions. Rats
406 that displayed a consistent baseline preference (>65% of time spent in one chamber) were excluded from
407 the study. Rats were pseudorandomly assigned to receive DAMGO in one of the larger chambers, and
408 assignments were counterbalanced for each cohort.

409 During conditioning sessions, microinjections were performed as described above through the intra-LHb
410 cannulae just before the rat was confined to the designated chamber for 30 min. One saline or one
411 DAMGO microinfusion was administered per conditioning session, morning and afternoon pairing
412 sessions were at least 4 h apart, and the order of administration was alternated on each day of
413 conditioning. On test day, rats were allowed to freely explore the chambers for 30 min and time spent (s)
414 in each partition was recorded. Difference score was defined as (Time spent in DAMGO-paired chamber)
415 - (Time spent in saline-paired chamber).

416 For ChR2 activation studies, rats were acclimated to handling and attachment of fiber cables to fiber
417 implants in a neutral environment. On procedure days, fiber implants were connected to optic fiber cables
418 attached to a 1x 2 fiber optic rotary joint (Doric Lenses, Quebec, Canada). A laser light source (MBL 473,
419 OEM Laser Systems, East Lansing, MI) was used with light intensity at the end of the output fiber
420 adjusted to 80-120 mW/mm^2. Light stimulation (5 ms pulses at 20 Hz) commenced upon placement of
421 rats into the designated chamber of a custom built apparatus on conditioning days. During baseline and
422 testing sessions, the time spent in each chamber was recorded using a webcam and analyzed using Viewer
423 software (Biobserve, Bonn, Germany).

424 ***Brain removal and immunohistochemistry***

425 Rats were deeply anesthetized with an intraperitoneal injection of Euthasol (0.1 mg/kg, Virbac Animal
426 Health, Fort Worth, TX) after 0.3 µl of Chicago Sky Blue (in 2% PBS) was injected through the cannulae
427 to mark injection locations. After becoming unresponsive to noxious stimuli, the rats were transcardially
428 perfused with 400 mL of saline, followed by 400 mL of 4% paraformaldehyde (PFA) in 0.1 M phosphate
429 buffer. The brains were extracted and immersion-fixed in PFA for 2 h at room temperature (RT), washed
430 two times with PBS to remove excess PFA, and stored in 1X PBS at 4ºC until they were sectioned (50
431 µm) using a vibratome (Leica VT 1000 S). Sections were mounted on slides using VECTASHIELD ®
432 mounting medium (Vector Laboratories, Burlingame, CA, USA). Images were taken under a Zeiss Stemi
433 2000-C (Pleasanton, CA) using an Amscope MD800E running AmScope x64 3.0 Imaging Software.

434 To label biocytin filled cells after slice electrophysiology recordings, slices were washed three times for 5
435 min each with PBS (Gibco, Waltham, MA), then blocked with a solution containing: bovine serum
436 albumin (0.2%), normal goat serum (5%) and Tween20 (0.3%; Sigma-Aldrich, St. Louis, MO) for 2 h at
437 RT. Slices were incubated in DTAF-streptavidin (1:200; Jackson Immuno Research) diluted in PBS +
438 0.3% Tween20 for 48 h at 4° C. After five, 10-min rinses, brain slices were mounted onto glass slides as
439 above and imaged using a Zeiss Axioskop upright microscope (2.5X, NA = 0.075 or Plan Apochromat
440 20X, NA = 0.75).

441 ***Electrophysiology***

442 Rats were deeply anesthetized with isoflurane, decapitated, and brains were quickly removed into ice-cold
443 artificial cerebrospinal fluid (aCSF) consisting of (in mM): 119 NaCl, 2.5 KCl, 1.0 NaH_2PO_4, 26.2
444 $NaHCO_3$, 11 glucose, 1.3 $MgSO_4$, 2.5 $CaCl_2$, saturated with 95% O_2-5% CO_2, with a measured osmolarity
445 310–320 mOsm/L. Two hundred µm coronal sections through the LHb were cut with a Leica VT 1000 S
446 vibratome. Slices were incubated in oxygenated aCSF at 33 °C and allowed to recover for at least one
447 hour. A single slice was placed in the recording chamber and continuously superfused at a rate of

448 2 mL/min with oxygenated aCSF. Neurons were visualized with an upright microscope (Zeiss
449 AxioExaminer.D1) equipped with infrared-differential interference contrast, Dodt optics, and fluorescent
450 illumination. Whole cell recordings were made at 34°C using borosilicate glass microelectrodes (3-5 MΩ)
451 filled with K-gluconate internal solution containing (in mM): 123 K-gluconate, 10 HEPES, 8 NaCl, 0.2
452 EGTA, 2 MgATP, 0.3 Na_3GTP, and 0.1% biocytin (pH 7.2 adjusted with KOH; 275 mOsm/L). Liquid
453 junction potentials were not corrected during recordings. Input and series resistance were monitored
454 throughout voltage clamp experiments with a −4 mV step every 30 seconds. Series resistance was
455 required to be 5-30 MΩ and cells with series resistance changes > 25% were excluded.

456 Signals were recorded using a patch clamp amplifier (Axopatch 1D, Molecular Devices, San Jose, CA or
457 IPA, Sutter Instruments, Novato, CA). Signals were filtered at 5 kHz and collected at 20 kHz using IGOR
458 Pro (Wavemetrics) or collected at 10 kHz using SutterPatch software (Sutter Instruments). Light evoked
459 EPSCs and IPSCs were evoked by two blue light pulses (473 nm, 1-10 ms) administered 50 ms apart,
460 once every 30 s. LHb recordings were generally made in LHb subregions enriched in ChR2-expressing
461 fibers. Recordings were made in voltage-clamp mode, with membrane potential clamped at $V_m = -60$ mV
462 and −40 mV, for EPSCs and IPSCs respectively. Light was delivered by an LED coupled to an optic fiber
463 aimed at the recorded cell (7-10 mW). To calculate connectivity rates, only the first neuron patched per
464 slice was included in order to avoid over sampling from slices or animals with lower infection rates.

465 *Data analysis for electrophysiology*. Light pulses were considered to reveal synaptic connections when
466 three conditions were met: (1) the average of 8 traces showed a deviation from baseline $I_{holding}$ such that
467 the mean trace exceeded 4 SD of 10 ms baseline period within the 10 ms window after initiation of light
468 pulse, (2) the putative response was observed in at least 3 independent trials, and (3) the delays from the
469 light stimulation onset of putative responses were time locked (<1 ms jitter) across trials. Latency was
470 calculated as time from start of light pulse to when the rate of rise exceeded −40,000 V/s. In some cases
471 DNQX (10 μM) or gabazine (10 μM) was bath applied to confirm inward and outward currents as AMPA
472 or $GABA_A$ receptor-mediated, respectively. All measurements of DAMGO effects on EPSCs were

473 completed in the presence of gabazine. After recordings, slices were drop fixed in 4% PFA for at least 2
474 h at 4°C and processed for biocytin labeling.

475 ***Combined retrograde tracing and* in situ *hybridization***

476 *Tracer injections*. Male Sprague Dawley rats (300-500 g) were anesthetized with 2-5% isoflurane. 1%
477 Fluoro-Gold (FG; FluoroChrome LLC) solution in a 0.1M cacodylate buffer (pH 7.5) was delivered
478 unilaterally into the LHb (−3.4 mm AP, ± 0.9 mm ML, and −5.4 mm DV) iontophoretically through a
479 stereotaxically positioned glass micropipette (18-25 µm inner diameter) by applying 1 µA, 7 s pulses at
480 14 s intervals for 20 min. The micropipette was then left in place for an additional 10 min to prevent
481 backflow. Following surgery, rats were singly housed and perfused 3 weeks later.

482 *Tissue Preparation.* Rats were anesthetized with chloral hydrate (0.5 ml/kg) and perfused transcardially
483 with 4% (w/v) PFA in 0.1M phosphate buffer treated with diethylpyrocarbonate (DEPC), pH 7.3. Brains
484 were post-fixed in 4% PFA for 2 h before being transferred to an 18% sucrose solution (w/v in 0.1M
485 PBS) and stored overnight at 4°C. Coronal sections of the LHb (30 µm) and LPO (16 µm) were prepared.

486 *Phenotyping of retrogradely labeled cells by immunocytochemistry and in situ hybridization.* Sections in
487 the LPO were incubated for 2 h at 30°C with rabbit anti-FG antibody (1:500; AB153; Millipore)
488 supplemented with RNAsin. Sections were then incubated in biotinylated goat anti-rabbit antibody
489 (1:200; BA1000; Vector Laboratories) for 1 h at 30 °C. Sections were then rinsed and treated with 0.2N
490 HCl, rinsed, and then acetylated in 0.25% acetic anhydride in 0.1 M triethanolamine. Subsequently,
491 sections were rinsed and post-fixed with 4% PFA, rinsed, and then incubated in a hybridization buffer for
492 2 h at 55°C.

493 Hybridization was then performed for radioactive detection of MOR mRNA by hybridizing sections for
494 16 h at 55°C with [35S]- and [33P]-labeled (107 c.p.m./mL) single-stranded antisense probes. Following
495 hybridization, sections were treated with 4 µg/mL of RNAse A at 37°C for 1 h, washed with 1X saline-
496 sodium citrate and 50% formamide for 1 h at 55°C, and then with 0.1X saline-sodium citrate at 68°C for 1

497 h. To visualize FG(+) cells, sections were rinsed with PBS and incubated for 1 h at RT in avidin-
498 biotinylated horseradish peroxidase (1:100, ABC kit; Vector Laboratories). Sections were then rinsed, and
499 the peroxidase reaction was developed with 0.05% 3,3'-diaminobenzidine tetrahydrochloride (DAB) and
500 0.003% H_2O_2. Sections were then photographed under bright field illumination and mounted on coated
501 slides. Finally, slides were dipped in Ilford K.5 nuclear tract emulsion (Polysciences; 1:1 dilution in
502 double-distilled water) and exposed in the dark at 4°C for 3-4 weeks before development and photographs
503 of silver-grain epiluminescence.

504 *Data analysis of in situ hybridization studies.* Methods for analysis of *in situ* hybridization material have
505 been described previously[46]. Briefly, pictures were adjusted to match contrast and brightness by using
506 Adobe Photoshop (Adobe Systems). Cell counting was completed independently by three scorers blind to
507 the hypothesis of the study. Radioactive *in situ* material was analyzed using epiluminescence to increase
508 the contrast of silver grains as described previously[59]. FG(+) cells (detected by fluorescence and brown
509 DAB-label) were evaluated for the presence of MOR mRNA: a cell was considered to express MOR
510 mRNA when its soma contained concentric aggregates of silver grains that exceeded background levels.

511 ***Fiber photometry***

512 *Surgery.* Male and female VGluT2::Cre mice (20-30 g; 6-12 weeks) were anesthetized with 1-5%
513 isoflurane and secured to a stereotaxic frame. Using a Micro4 controller and UltraMicroPump, 0.2 µL of a
514 retrograde, Cre-dependent HSV encoding GCaMP6m (HSV-hEF1α-LS1L-GCaMP6m) was injected into
515 the LHb (-1.5 mm AP, +0.45 mm ML, -3.0 mm DV). Syringes were left in place for 7-10 min following
516 injections to minimize diffusion. For fiber photometry calcium imaging experiments, a 400 µm core optic
517 fiber (Doric Lenses) embedded in a 2.5 mm ferrule was implanted over the LPO (+0.5 mm AP, +0.8 mm
518 ML, -5.05 mm DV) and secured to the skull using #000 screws (Fasteners and Metal products Corp;
519 #000-120 X 1/16) and dental cement. Following surgery, mice recovered on a warm heating pad before

being transferred back to the vivarium home cage. Three weeks after the virus and fiber surgery, mice were given either SNI or sham control surgery as described above.

Recording. Signals from GCaMP6 were recorded across 10 trials of stimulation in the Hargreaves test using a Plantar Test Instrument. The onset and offset time for each trial was digitized and sent to an RZ5D (Tucker Davis Technologies). For the acquisition of LPO→LHB activity, GCaMP6 was excited at two wavelengths (490nm, calcium-dependent signal and 405 nm isosbestic control) by amplitude modulated signals from two light-emitting diodes reflected off dichroic mirrors and coupled into a 400µm 0.48NA optic fiber. Signals emitted from GCaMP6m and its isosbestic control channel then returned through the same optic fiber and were acquired using photoreceiver (Doric Lenses), digitized at 1kHz, and then recorded by a real-time signal processor (RZ5D; Tucker Davis Technologies) running the Synapse software suite. Analysis of the resulting signal was then performed using custom-written MATLAB scripts available in a general release form at https://github.com/djamesbarker/FiberPhotometry. Briefly, changes in fluorescence across the experimental session (ΔF/F) were calculated by smoothing signals from the isosbestic control channel, scaling the isosbestic control signal by regressing it on the smoothed GCaMP signal, and then generating a predicted 405 nm signal using the linear model generated during the regression. Calcium independent signals on the predicted 405 nm channel were then subtracted from the raw GCaMP signal to remove movement, photo-bleaching, and fiber bending artifacts. Signals from the GCaMP channel were then divided by the control signal to generate the ΔF/F. Peri-event histograms were then created by averaging changes in fluorescence (ΔF/F) across repeated trials during windows encompassing behavioral events of interest. The area under the curve (AUC) was calculated for a pre-stimulation 5 s baseline commencing -10 s before paw withdrawal and for the 5 s period initiated with paw withdrawal.

542 ***Anterograde tracing from the ACC***

543 In rats, unilateral injections of AAV2-hSyn-hChR2(H134R)-mCherry (759 nL) were made throughout
544 anteroposterior range of the ACC (+2.6 to -0.4 mm AP, -0.4 to -0.5 mm ML, -2.6 to -2.8 mm DV). Rats
545 were perfused and brains fixed five weeks later, as described above. Coronal sections (50 μm) containing
546 the ACC and the LHb were collected. After verification of the injection site, every sixth slice containing
547 the LHb was rinsed twice with PBS. Tissue was pre-permeabilized in 1:1 EtOH:PBS for 30 min at 4°C,
548 rinsed briefly in PBS before blocked in 3% H_2O_2 for 10 min. Following PBS washes (3x5 min), tissue
549 was blocked in solution containing normal goat serum (NGS, 10%) for 1 h at RT. Slices were incubated
550 in rabbit anti-mCherry antibody (1:5000 in PBS + 0.3% Triton X100 + NGS 10%; Abcam) overnight at
551 4°C. After PBS washes (4x10 min), slices were incubated in biotinylated goat anti-rabbit secondary
552 antibody (1:200 in PBS; Vector Laboratories) for 2 h at 4°C. Following PBS wash (4x10 min), slices
553 were incubated in VECTASTAIN® ABC Reagent (VECTASTAIN® ABC Kit, Vector Laboratories) for
554 30 min followed by peroxidase substrate (DAB Substrate Kit, Vector Laboratories) for 10 min. Once dark
555 brown DAB precipitate formed, slices were rinsed in PBS (5x5 min), mounted on glass slides, and cover
556 slipped with DEPEX (Electron Microscopy Sciences). DAB-stained fibers were visualized under
557 brightfield illumination and quantified in Stereo Investigator software (MBF Bioscience) using the virtual
558 isotropic space balls probe[60].

559 ***General experimental design***

560 For behavioral experiments, subject numbers were determined by pilot studies and power analyses (power
561 = 0.80, significance level = 0.05, effect size = 15-30%). All behavioral experiments were performed
562 blinded to experimental condition. For immunohistological experiments, three animals with injections
563 targeted at the anterior, middle, and posterior ACC were used to obtain a comprehensive estimation of
564 fibers projecting to the LHb. Electrophysiology experiments were conducted blind to injection site.

565 ***Quantification and statistical analysis***

566 Data are expressed as mean ± SEM or mean with 25th and 75th percentiles as indicated in figure legends
567 and text. Significance was set at $p < 0.05$. Datasets were evaluated to determine whether parametric or
568 non-parametric statistical approaches were most appropriate as indicated in Supplemental Table 1. All
569 tests were two tailed, and statistical analyses were performed in GraphPad Prism or R. The bandwidth for
570 electrophysiology violin plots was determined by Silverman's rule of thumb in Plotly for Python; violin
571 plots for behavior experiments were constructed with heavy kernel density estimations in Prism. Sample
572 sizes are reported in figure panels, legends, and Supplementary Table 1. Outliers, including extreme
573 outliers, are reported in Supplementary Table 1 and were not removed from datasets.

574

575 **Reporting summary**

576 Further information on research design is available in the Nature Research Reporting Summary linked to
577 this paper.

578

579 **Data availability**

580 All data described in the main text or extended data are available from the corresponding author upon
581 request.

582

583 **Acknowledgements**

584 The authors would like to thank Ryan Carothers, Gabrielle Mintz, Lucy He, Venkateswaran Ganesh, and
585 Benjamin Snyder for their technical assistance with histology, stereotaxic surgeries, and behavioral
586 studies. This work was supported by National Institutes of Health grants R01DA042025 (to E.B.M.), K08

NS097632 (to M.W.W.), and the Intramural Research Program (IRP) of the National Institute on Drug Abuse (IRP/NIDA/NIH) and a NIDA K99/R00 pathway to independence award (DA043572) to D.J.B.

Competing Interests Statement

The authors have no competing interests.

References

1. Matsumoto, M. & Hikosaka, O. Representation of negative motivational value in the primate lateral habenula. *Nat Neurosci* **12**, 77–84 (2009).
2. Benabid, A. L. & Jeaugey, L. Cells of the rat lateral habenula respond to high-threshold somatosensory inputs. *Neurosci Lett* **96**, 289–94 (1989).
3. Dafny, N. & Qiao, J. T. Habenular neuron responses to noxious input are modified by dorsal raphe stimulation. *Neurol. Res.* **12**, 117–121 (1990).
4. Nagao, M., Kamo, H., Akiguchi, I. & Kimura, J. Induction of c-Fos-like protein in the lateral habenular nucleus by persistent noxious peripheral stimulation. *Neurosci. Lett.* **151**, 37–40 (1993).
5. Huang, T. *et al.* Identifying the pathways required for coping behaviours associated with sustained pain. *Nature* **565**, 86–90 (2019).
6. Matsumoto, M. & Hikosaka, O. Lateral habenula as a source of negative reward signals in dopamine neurons. *Nature* **447**, 1111–1115 (2007).
7. Li, B. *et al.* Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. *Nature* **470**, 535–539 (2011).
8. Poller, W. C., Madai, V. I., Bernard, R., Laube, G. & Veh, R. W. A glutamatergic projection from the lateral hypothalamus targets VTA-projecting neurons in the lateral habenula of the rat. *Brain Res* **1507**, 45–60 (2013).

611 9. Herkenham, M. & Nauta, W. J. Afferent connections of the habenular nuclei in the rat. A horseradish
612 peroxidase study, with a note on the fiber-of-passage problem. *J Comp Neurol* **173**, 123–46 (1977).
613 10. Vertes, R. P. Analysis of projections from the medial prefrontal cortex to the thalamus in the rat, with
614 emphasis on nucleus reuniens. *J. Comp. Neurol.* **442**, 163–187 (2002).
615 11. Yetnikoff, L., Cheng, A. Y., Lavezzi, H. N., Parsley, K. P. & Zahm, D. S. Sources of input to the
616 rostromedial tegmental nucleus, ventral tegmental area, and lateral habenula compared: A study in
617 rat. *J Comp Neurol* **523**, 2426–56 (2015).
618 12. Kim, U. & Lee, T. Topography of descending projections from anterior insular and medial prefrontal
619 regions to the lateral habenula of the epithalamus in the rat. *Eur J Neurosci* **35**, 1253–69 (2012).
620 13. Araki, M., McGeer, P. L. & Kimura, H. The efferent projections of the rat lateral habenular nucleus
621 revealed by the PHA-L anterograde tracing method. *Brain Res.* **441**, 319–330 (1988).
622 14. Quina, L. A. *et al.* Efferent pathways of the mouse lateral habenula. *J Comp Neurol* **523**, 32–60
623 (2015).
624 15. Cohen, S. R. & Melzack, R. Morphine injected into the habenula and dorsal posteromedial thalamus
625 produces analgesia in the formalin test. *Brain Res.* **359**, 131–139 (1985).
626 16. Margolis, E. B. & Fields, H. L. Mu Opioid Receptor Actions in the Lateral Habenula. *PLoS One* **11**,
627 e0159097 (2016).
628 17. Decosterd, I. & Woolf, C. J. Spared nerve injury: an animal model of persistent peripheral
629 neuropathic pain. *PAIN* **87**, 149–158 (2000).
630 18. Miaskowski, C. *et al.* Does opioid analgesia show a gender preference for females? *Pain Forum* **8**,
631 34–44 (1999).
632 19. Kest, B., Sarton, E. & Dahan, A. Gender differences in opioid-mediated analgesia: animal and human
633 studies. *Anesthesiology* **93**, 539–547 (2000).
634 20. Kepler, K. L. *et al.* Gender effects and central opioid analgesia. *Pain* **45**, 87–94 (1991).

635 21. Thompson, S. J. *et al.* Chronic neuropathic pain reduces opioid receptor availability with associated
636 anhedonia in rat. *Pain* **159**, 1856–1866 (2018).
637 22. Porreca, F. *et al.* Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve
638 injury. *Brain Res.* **795**, 197–203 (1998).
639 23. Zhang, X. *et al.* Down-regulation of mu-opioid receptors in rat and monkey dorsal root ganglion
640 neurons and spinal cord after peripheral axotomy. *Neuroscience* **82**, 223–240 (1998).
641 24. Shabel, S. J., Proulx, C. D., Trias, A., Murphy, R. T. & Malinow, R. Input to the lateral habenula
642 from the basal ganglia is excitatory, aversive, and suppressed by serotonin. *Neuron* **74**, 475–481
643 (2012).
644 25. Lecca, S. *et al.* Aversive stimuli drive hypothalamus-to-habenula excitation to promote escape
645 behavior. *eLife* **6**, (2017).
646 26. Hu, H., Cui, Y. & Yang, Y. Circuits and functions of the lateral habenula in health and in disease.
647 *Nat. Rev. Neurosci.* **21**, 277–295 (2020).
648 27. Root, D. H., Mejias-Aponte, C. A., Qi, J. & Morales, M. Role of glutamatergic projections from
649 ventral tegmental area to lateral habenula in aversive conditioning. *J Neurosci* **34**, 13906–10 (2014).
650 28. Barker, D. J. *et al.* Lateral Preoptic Control of the Lateral Habenula through Convergent Glutamate
651 and GABA Transmission. *Cell Rep.* **21**, 1757–1769 (2017).
652 29. Fields, H. State-dependent opioid control of pain. *Nat Rev Neurosci* **5**, 565–75 (2004).
653 30. Tooley, J. *et al.* Glutamatergic Ventral Pallidal Neurons Modulate Activity of the Habenula-
654 Tegmental Circuitry and Constrain Reward Seeking. *Biol. Psychiatry* **83**, 1012–1023 (2018).
655 31. Johansen, J. P., Fields, H. L. & Manning, B. H. The affective component of pain in rodents: direct
656 evidence for a contribution of the anterior cingulate cortex. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 8077–
657 8082 (2001).
658 32. LaGraize, S. C., Borzan, J., Peng, Y. B. & Fuchs, P. N. Selective regulation of pain affect following
659 activation of the opioid anterior cingulate cortex system. *Exp. Neurol.* **197**, 22–30 (2006).

660 33. Kim, U. & Chang, S. Y. Dendritic morphology, local circuitry, and intrinsic electrophysiology of
661 neurons in the rat medial and lateral habenular nuclei of the epithalamus. *J Comp Neurol* **483**, 236–50
662 (2005).
663 34. Flanigan, M. E. *et al.* Orexin signaling in GABAergic lateral habenula neurons modulates aggressive
664 behavior in male mice. *Nat. Neurosci.* **23**, 638–650 (2020).
665 35. Zhang, L. *et al.* A GABAergic cell type in the lateral habenula links hypothalamic homeostatic and
666 midbrain motivation circuits with sex steroid signaling. *Transl. Psychiatry* **8**, 50 (2018).
667 36. Quina, L. A., Walker, A., Morton, G., Han, V. & Turner, E. E. GAD2 Expression Defines a Class of
668 Excitatory Lateral Habenula Neurons in Mice that Project to the Raphe and Pontine Tegmentum.
669 *eNeuro* **7**, (2020).
670 37. Wallace, M. L. *et al.* Anatomical and single-cell transcriptional profiling of the murine habenular
671 complex. *eLife* **9**, (2020).
672 38. Mansour, A., Khachaturian, H., Lewis, M. E., Akil, H. & Watson, S. J. Autoradiographic
673 differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. *J. Neurosci.*
674 *Off. J. Soc. Neurosci.* **7**, 2445–2464 (1987).
675 39. Kang, S. *et al.* Downregulation of M-channels in lateral habenula mediates hyperalgesia during
676 alcohol withdrawal in rats. *Sci. Rep.* **9**, 2714 (2019).
677 40. Li, J., Li, Y., Zhang, B., Shen, X. & Zhao, H. Why depression and pain often coexist and mutually
678 reinforce: Role of the lateral habenula. *Exp. Neurol.* **284**, 106–113 (2016).
679 41. Li, Y. *et al.* Role of the Lateral Habenula in Pain-Associated Depression. *Front. Behav. Neurosci.* **11**,
680 31 (2017).
681 42. Weiss, T. & Veh, R. W. Morphological and electrophysiological characteristics of neurons within
682 identified subnuclei of the lateral habenula in rat brain slices. *Neuroscience* **172**, 74–93 (2011).
683 43. Metzger, M. *et al.* Habenular connections with the dopaminergic and serotonergic system and their
684 role in stress-related psychiatric disorders. *Eur. J. Neurosci.* (2019) doi:10.1111/ejn.14647.

685 44. Meye, F. J. *et al.* Shifted pallidal co-release of GABA and glutamate in habenula drives cocaine
686 withdrawal and relapse. *Nat. Neurosci.* **19**, 1019–1024 (2016).
687 45. Shabel, S. J., Proulx, C. D., Piriz, J. & Malinow, R. Mood regulation. GABA/glutamate co-release
688 controls habenula output and is modified by antidepressant treatment. *Science* **345**, 1494–8 (2014).
689 46. Root, D. H. *et al.* Selective Brain Distribution and Distinctive Synaptic Architecture of Dual
690 Glutamatergic-GABAergic Neurons. *Cell Rep.* **23**, 3465–3479 (2018).
691 47. Newman, H. M., Stevens, R. T. & Apkarian, A. V. Direct spinal projections to limbic and striatal
692 areas: anterograde transport studies from the upper cervical spinal cord and the cervical enlargement
693 in squirrel monkey and rat. *J. Comp. Neurol.* **365**, 640–658 (1996).
694 48. Burstein, R., Cliffer, K. D. & Giesler, G. J. Direct somatosensory projections from the spinal cord to
695 the hypothalamus and telencephalon. *J. Neurosci. Off. J. Soc. Neurosci.* **7**, 4159–4164 (1987).
696 49. Hori, T., Oka, T., Hosoi, M. & Aou, S. Pain modulatory actions of cytokines and prostaglandin E2 in
697 the brain. *Ann. N. Y. Acad. Sci.* **840**, 269–281 (1998).
698 50. Ono, T. & Nakamura, K. Learning and integration of rewarding and aversive stimuli in the rat lateral
699 hypothalamus. *Brain Res.* **346**, 368–373 (1985).
700 51. Almli, C. R. & McMullen, N. T. Ontogeny of lateral preoptic unit activity in rats. *Brain Res. Bull.* **4**,
701 773–781 (1979).
702 52. Vowles, K. E. *et al.* Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review
703 and data synthesis. *Pain* **156**, 569–576 (2015).
704 53. Zadina, J. E. *et al.* Endomorphin analog analgesics with reduced abuse liability, respiratory
705 depression, motor impairment, tolerance, and glial activation relative to morphine.
706 *Neuropharmacology* **105**, 215–227 (2016).
707 54. Ehrlich, A. T. *et al.* Expression map of 78 brain-expressed mouse orphan GPCRs provides a
708 translational resource for neuropsychiatric research. *Commun. Biol.* **1**, 102 (2018).

709 55. Wagner, F., Bernard, R., Derst, C., French, L. & Veh, R. W. Microarray analysis of transcripts with
710 elevated expressions in the rat medial or lateral habenula suggest fast GABAergic excitation in the
711 medial habenula and habenular involvement in the regulation of feeding and energy balance. *Brain*
712 *Struct. Funct.* **221**, 4663–4689 (2016).
713 56. Broms, J. *et al.* Monosynaptic retrograde tracing of neurons expressing the G-protein coupled
714 receptor Gpr151 in the mouse brain. *J. Comp. Neurol.* **525**, 3227–3250 (2017).
715 57. Paxinos, G. & Watson, C. *The Rat Brain in Stereotaxic Coordinates, Compact*. (Academic Press,
716 1997).
717 58. Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. & Yaksh, T. L. Quantitative assessment of
718 tactile allodynia in the rat paw. *J. Neurosci. Methods* **53**, 55–63 (1994).
719 59. Yamaguchi, T., Wang, H.-L., Li, X., Ng, T. H. & Morales, M. Mesocorticolimbic glutamatergic
720 pathway. *J. Neurosci. Off. J. Soc. Neurosci.* **31**, 8476–8490 (2011).
721 60. Mouton, P. R., Gokhale, A. M., Ward, N. L. & West, M. J. Stereological length estimation using
722 spherical probes. *J. Microsc.* **206**, 54–64 (2002).
723

724

Extended Data Figure 2



Extended Data Figure 2. *Neurons receiving functional synaptic inputs from the five brain regions showing connectivity were distributed throughout the LHb.* Locations of neurons found connected using whole-cell recordings from optogenetic stimulation of terminals arising from each input tested. Locations are based on biocytin immunohistochemistry and low magnification images taken on the recording microscope where the recorded cell is centered within the field of view. Color indicates source of innervation.

Extended Figure 3



Extended Data Figure 3. *ACC minimally innervates the LHb.* **a**, Diagram of the extent of unilateral AAV2-hSyn-hChR2(H134R)-mCherry injection sites (n = 9 male rats) throughout anteroposterior range of the ACC for anterograde tracing study. **b,** Example ipsilateral DAB-positive fibers (black) visualized under brightfield illumination. Fibers heavily innervate the MDL, which abuts the lateral edge of the LHb, while sparse to no fibers innervate the LHb. Contralateral innervation of LHb and MDL was negligible compared to the ipsilateral side, and therefore were omitted from our analysis. (Left) Scale bar = 250 µm. (Right) Scale bar = 50 µm. **c**, Average stereologically-quantified DAB-positive fiber lengths throughout anteroposterior range of the LHb, compared to the MDL innervation in the same coronal slice. Mann-Whitney test, two-tailed: U = 0, p = 0.0006.

Extended Data Figure 4



Extended Data Figure 4. *Sources of glutamatergic inputs to the rat LHb vary in strength and delay in synaptic transmission.* **a**, We observed some variations between inputs in the mean light evoked EPSCs (V_m = -60 mV). In particular, excitatory inputs from the VTA were consistently small: Kruskal-Wallis $\chi2$ = 25.5, df = 4, p = 0.00004, followed by Dunn Test for pairwise comparisons. **b**, Differences were also detected in the delay to the onset of light evoked EPSCs to LHb neurons from these different sources, with inputs from LH showing the fastest response. Although these data deviate from a normal distribution (Shapiro's test, p = 0.0000001), KDEs (violins) are consistent with continuous distributions, suggesting reliable polysynaptic events were rarely detected. **c**, We observed some variations between inputs in the mean light evoked IPSCs (V_m = -40 mV). While there were no statistically significant differences in amplitudes detected, the mean inhibitory input from the VP was particularly small: Kruskal-Wallis $\chi2$ = 2.3, df = 4, p = 0.7. ** $p < 0.01$, *** $p < 0.005$, **** $p < 0.0005$

Extended Data Figure 5



Extended Data Figure 5. *Optogenetic experiments detect local glutamate, but not GABA, functional connections in rat LHb.* AAV2-hSyn-hChR2(H134R)-mCherry was stereotaxically injected into the LHb at least 4 weeks prior to *ex vivo* whole cell recordings in the LHb to detect local synaptic connections. Neurons were recorded blind to ChR2 expression, therefore in some cases the patched neuron expressed ChR2. Therefore, in addition to connectivity criteria used for other afferent inputs, in these experiments only light evoked inward currents that were blocked by 10 µM DNQX were considered glutamatergic connections, and direct ChR2 induced inward currents were subtracted out for the quantification illustrated here. Each cell was probed for both glutamate and GABA inputs in voltage clamp by holding neurons at V_m = -60 mV and -40 mV, light pulse durations 1, 5, and 10 ms durations. **a**, Example recording at V_m = -60 mV showing a light evoked response that was blocked by DNQX. **b**, Example recording at V_m = -40 mV with minimal outward current response within 7 ms of light pulse. **c**, Summary of all LHb recordings tested in this experiment. Filled circles represent cells where responses could be classified as local ChR2 induced synaptic transmission. When no clear response was detected, the measure indicated is the difference between the mean $I_{holding}$ of the baseline 100 ms period just prior to the light pulse and the mean $I_{holding}$ 2 ms period starting 2 ms after initiation of the light pulse, consistent with monosynaptic delay timing. None of the recordings made at V_m = -40 mV met the criteria for a response to light stimulation with an outward current.

Extended Data Figure 6



Extended Data Figure 6. *Isolated monosynaptic glutamatergic inputs from LPO to LHb neurons are inhibited by MOR activation.* **a,** Example light evoked EPSC responses in an LHb neuron from a rat with ChR2 expression in LPO neurons. This response persisted in monosynaptic isolation by 500 nM TTX and 100 µM 4 AP (green), and this isolated response was inhibited by 500 nM DAMGO (magenta). **b**, Summary of DAMGO effects on isolated monosynaptic EPSC inputs to LHb neurons expressed as % of baseline monosynaptic response (left) and as raw EPSC magnitudes (right). Paired t-test, df = 4, t = -5.1, p = 0.007. ** p < 0.01

Extended Data Figure 7



Extended Data Figure 7. *Mice with SNI show hypersensitivity to heat and increased activity in LHb-projecting LPO neurons during paw withdrawal from thermal stimulation.* **a,** Mice with SNI show a reduced latency to withdraw their paw following thermal stimulation in the Hargreaves task. Unpaired t-test, t(12) = 3.007, p = 0.011. **b,** VGluT2-expressing LPO neurons that project to the LHb expressed GCaMP6m and showed a greater calcium response during paw withdrawal to Hargreaves thermal stimulation (area under the curve, deviation from baseline fluorescence) in SNI animals (n = 5) compared to sham controls (n = 9): Two-way ANOVA, F(1,12) = 5.4, p = 0.038; Holm-Sidak post-hoc test, p = 0.0074. ** p < 0.01

Extended Data Figure 8



Extended Data Figure 8. Locations and spread of bilateral ChR2 injections to the LPO in rats used for *in vivo* optogenetic experiments.

Supplementary Table 1: Assumption testing on behavioral data

Experiment	Figure	# animals; # Outliers; # extreme outliers	Shapiro-Wilk Test of Normality (across all groups) Statistic; p val	Test for Homogeneity of Variances Statistic; p val (Test used)	Parametric test	Non-parametric test: Repeated measures Wilcoxon signed rank exact test V; p val
von Frey: Male; Sham; 10 µM DAMGO in LHb	1b	9; 0; 0	0.773; 0.000638	0.0760; 0.786 (Levene's Test)	n/a	1.5; 1
von Frey: Male; SNI; 10 µM DAMGO in LHb	1b	8; 0; 0	0.866; 0.0240	1.49; 0.242 (Levene's Test)	n/a	2; 0.05024
von Frey: Female; SNI; 10 µM DAMGO in LHb	1b	9; 2; 1	0.805; 0.00181	1.82; 0.196 (Levene's Test)	n/a	7; 0.07422
von Frey: Male; Sham; 10 µM DAMGO in i.c.v.	1b	9; 0; 0	0.768; 0.00055	0.0897; 0.768 (Levene's Test)	n/a	7; 0.5294
von Frey: Male; SNI; 10 µM DAMGO in i.c.v.	1b	12; 2; 2	0.756; 0.0000618	0.168; 0.686 (Levene's Test)	n/a	31; 0.08006
Place Conditioning: Male Sham/SNI; 10 µM DAMGO in LHb	1c	15; 4; 0	Sham x Baseline: 0.95; 0.726 SNI x Baseline: 0.94; 0.686 Sham x Test: 0.936; 0.542 SNI x Test: 0.840; 0.129	4.68; 0.0305 (Box M-test)	Two-way mixed design ANOVA two-way interaction F(1,13) =15.932; p = 0.002 effect of group on baseline: F = 0.293; adjusted p = 1 effect of group on test day: F = 11.3; adjusted p = 0.01 Paired t-tests, adjusted Sham: adjusted p = 1 SNI: adjusted p = 0.012	n/a
Place Conditioning: Sham vs. Male SNI; 10 µM DAMGO in i.c.v.	1c	21; 2; 0	Sham x Baseline: 0.901; 0.257 SNI x Baseline: 0.967; 0.872 Sham x Test: 0.971; 0.905 SNI x Test: 0.985; 0.997	23.9; 0.000000997 (Box M-test)	Two-way mixed design ANOVA two-way interaction F(1,19) =2.239; p = 0.151 Paired t-tests for non-significant two-way interaction: Sham: adjusted p = 0.286 SNI: adjusted p = 0.433	n/a
von Frey: Female; Sham; 100 µM DAMGO in LHb	1d	6; 0; 0	0.838; 0.026	0.493; 0.499 (Levene's Test)	n/a	5; 1
von Frey: Female; SNI; 100 µM DAMGO in LHb	1d	9; 1; 1	0.839; 0.00928	1.13; 0.306 (Levene's Test)	n/a	6; 0.4017
Place Conditioning: Female Sham/SNI; 100 µM DAMGO in LHb	1e	15; 3; 0	Sham x Baseline: 0.904 0.66 SNI x Baseline: 0.919; 0.384 Sham x Test: 0.87; 0.226 SNI x Test: 0.900; 0.250	8.59; 0.00339 (Box M-test)	Two-way mixed design ANOVA two-way interaction F(1,13) =6.234; p = 0.027 effect of group on baseline: F = 0.006; adjusted p = 1 effect of group on test day: F = 5.56; adjusted p = 0.07 Paired t-tests, adjusted Sham: adjusted p = 0.476 SNI: adjusted p = 0.0349	n/a
Fiber photometry; Sham vs. SNI mice	5b	14; not determined	not determined	not determined	Two-way mixed design ANOVA F(1,12) = 5.439; p= 0.038; Holm-Sidak post-hoc test, p = 0.0074	n/a
Place Conditioning; Male; mCherry vs. ChR2; 10 µM DAMGO in LHb	5e	16; 0; 0	mCherry x Baseline: 0.941; 0.618 ChR2 x Baseline: 0.913; 0.374	18.3; 0.0000186 (Box M-test)	Two-way mixed design ANOVA two-way interaction, F(1,14) = 9.982; p = 0.007 effect of group on baseline: F = 0.01; adjusted p = 1	n/a

			mCherry x Test: 0.914; 0.385 ChR2 x Test: 0.847; 0.0891		effect of group on test day: F = 12.5; adjusted p = 0.006 Paired t-tests, adjusted mCherry: adjusted p = 0.427 ChR2: adjusted p = 0.0027	
Hargreaves: Male; Sham; 10 µM DAMGO in LHb	ED 1a	9; 2; 0	0.966; 0.726	Bartlett's K-squared = 0.035658, df = 1, p-value = 0.8502 (Bartlett Test)	Paired t-test Df = 8; t = 1.06; p = 0.32	n/a
Hargreaves; Male; SNI; 10 µM DAMGO in LHb	ED 1a	8; 0; 0	0.941; 0.365	Bartlett's K-squared = 3.704 df = 1, p-value = 0.096 (Bartlett Test)	Paired t-test Df = 7; t = -1.92; p = 0.096	n/a
Hargreaves; Female; SNI; 10 µM DAMGO in LHb	ED 1a	9; 1; 1	0.944; 0.333	Bartlett's K-squared = 1.35 df = 1, p-value = 0.245 (Bartlett Test)	Paired t-test Df = 8; t = -1.4; p = 0.199	n/a
Hargreaves: Male; Sham; 10 µM DAMGO in i.c.v.	ED 1a	9; 3; 0	0.927; 0.174	0.840; 0.373 (Levene's Test)	Paired t-test Df = 8; t = -0.08; p = 0.938	n/a
Hargreaves; Male; SNI; 10 µM DAMGO in i.c.v.	ED 1a	8; 0; 0	0.941; 0.365	0.013; 0.911 (Levene's Test)	Paired t-test Df = 11; t = 3.2; p = 0.00846	n/a
von Frey; Male; Sham; 10 µM DAMGO in LHb	ED 1c	9; 0; 0	0.773; 0.000638	0.0760; 0.786 (Levene's Test)	n/a	1.5; 1
von Frey; Male; CFA; 10 µM DAMGO in LHb	ED 1c	9; 0; 0	0.903; 0.0639	3.80 0.0691 (Levene's Test)	Paired t-test Df = 8; t = -2.89; p = 0.0202	n/a
Hargreaves; Male; Sham; 10 µM DAMGO in LHb	ED 1d	9; 2; 0	0.966; 0.726	Bartlett's K-squared = 0.035658, df = 1, p-value = 0.8502 (Bartlett Test)	Paired t-test Df = 8; t = 1.06; p = 0.32	n/a
Hargreaves; Male; CFA; 10 µM DAMGO in LHb	ED 1d	9; 2; 2	0.858; 0.0113	0.0461 0.833 (Levene's Test)	n/a	12; 0.25
Place Conditioning; Male; Sham vs. CFA; 10 µM DAMGO in LHb	ED 1e	16; 3; 0	Sham x Baseline: 0.901; 0.257 CFA x Baseline: 0.94; 0.635 Sham x Test: 0.971; 0.905 CFA x Test: 0.828; 0.0774	13.4; 0.000253 (Box M-test)	Two-way mixed design ANOVA two-way interaction F(1,14) =0.474; p = 0.502 Paired t-tests for non-significant two-way interaction: Sham: adjusted p = 0.286 CFA: adjusted p = 0.761	n/a
ACC fiber innervation; Ipsi LHb vs. Ipsi MDL	ED 3c	9; 0; 0	not determined	not determined	n/a	Mann-Whitney test, two-tailed, U=0; p = 0.0006
Hargreaves; Sham vs. SNI mice	ED 7a	14; 3; 2	0.896; 0.0994	0.0012; 0.973 (Levene's Test)	Unpaired t-test Df = 12, t = 3.007, p = 0.0109	n/a
AUC summary: Hargreaves/Fiber photometry; Sham vs. SNI mice	ED 7b	14; 0; 0	Sham x Baseline: 0.979; 0.257 Sham x paw withdrawal: 0.932; 0.496 SNI x Baseline: 0.813; 0.103 SNI x paw withdrawal: 0.921; 0.538	53.4; 2.71 e-13 (Box M-test)	Two-way mixed design ANOVA F(1,12) = 5.439; p = 0.038; Holm-Sidak post-hoc test, p=0.0074	n/a